Eli Lilly | LLY - Заемный капитал





Заемный капитал Изменить Дата
AbbVie USD 64.53B 5.59B 2026-03
Abbott USD 29.64B 19.74B 2026-03
ALKERMES USD 1.48B 7.23M 2026-06
Amgen USD 51.86B 27M 2026-06
AstraZeneca USD 26.01B 46M 2026-06
Baxter International USD 8.62B 6M 2026-06
Biogen USD 7.29B 1B 2026-06
Bristol-Myers Squibb USD 42.09B 59M 2026-06
Coherus Biosciences USD 51.08M 496K 2025-12
Drreddys Laboratories INR 12.2B 12.07B 2026-03
Eli Lilly USD 47.86B 8.49B 2026-06
Gilead Sciences USD 20.86B 1.27B 2026-03
GlaxoSmithKline GBP 13.95B 65M 2026-06
Glaxosmithkline GBP 18.53B 1.29B 2026-03
J&J USD 37.34B 183M 2026-06
Medtronic USD 27.88B 255M 2025-12
Merck USD 51.08B 4.41B 2026-06
Neurocrine Biosciences USD 169.5M 500K 2023-03
Novartis USD 37.49B 42M 2026-06
Novartis USD 37.45B 7.86B 2026-03
Novo Nordisk DKK 121.79B 2.62B 2026-06
Perrigo USD 3.28B 337.7M 2026-06
Pfizer USD 60.5B 70M 2026-06
Phibro Animal Health USD 597.68M 5.92M 2026-03
Prestige Brands USD 2.02B 1.01B 2026-06
Regeneron Pharmaceuticals USD 1.99B 400K 2026-06
Roche Holding CHF 25.22B 2.21B 2026-06
Sanofi EUR 14.65B 806M 2026-06
Sanofi EUR 12.3B 3.42B 2026-03
United Therapeutics USD 100M 100M 2024-06
Zoetis USD 9.05B 3M 2026-06